局部麻醉下首次人体机器人辅助视网膜下药物递送
在牛津眼科医院开展的双眼随机对照手术试验纳入12例黄斑出血患者,按预定标准分为机器人辅助组和手动手术对照组各6例;所有患者均表现为继发于新生血管性年龄相关性黄斑变性的中心凹下出血。结果显示手术耐受良好且安全,两组手术总时长、注射完成时间及视网膜微创伤相似且无临床意义,除1例对照组外视网膜下出血在术后1个月均成功移位,两组视力中位增益相似。
要点
- 局部麻醉下机器人辅助视网膜下注射组织型纤溶酶原激活剂(TPA)在全部病例中安全完成。
- 两组手术总时长、注射完成时间和视网膜微创伤相似且无临床意义。
- 术后1个月除1例对照组外视网膜下出血均成功移位,两组视力中位增益相似。
核心结论
- 这项首次人体研究证明高精度机器人辅助视网膜下药物递送作为黄斑下出血手术管理的一部分具有可行性和安全性。
研究设计与样本
- 双眼随机对照手术试验(ClinicalTrials.gov标识号NCT03052881),在牛津眼科医院开展,共招募12例患者,机器人辅助组和手动手术对照组各6例。
主要发现
- 所有参与者对手术耐受良好,所有病例均安全完成手术。
- 两组手术总时长、完成注射所需时间和视网膜微创伤相似且无临床意义。
- 术后1个月除1例对照组受试者外视网膜下出血均成功移位,两组视力中位增益相似。
关键数值与推荐
- 入组患者均为继发于新生血管性年龄相关性黄斑变性的中心凹下出血导致急性视力丧失。
- 先行标准玻璃体切除术,在术中光学相干断层扫描引导下经机器人辅助或传统手动技术行视网膜下注射TPA,机器人部分包括将套管推进穿过视网膜并在脚踏控制注射最多100 µL TPA溶液期间稳定套管。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To report the results of a first-in-human study using a robotic device to assist subretinal drug delivery in patients undergoing vitreoretinal surgery for macular hemorrhage. DESIGN: Double-armed, randomized controlled surgical trial (ClinicalTrials.gov identifier: NCT03052881). METHODS: The study was performed at the Oxford Eye Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom. In total, 12 participants were recruited-6 in the robot-assisted and 6 in the control manual surgery arm according to the prespecified inclusion and exclusion criteria. All subjects presented with acute loss of vision owing to a subfoveal hemorrhage secondary to neovascular age-related macular degeneration. After standard vitrectomy, intraoperative optical coherence tomography-guided subretinal injection of tissue plasminogen activator (TPA) was performed by either robot-assisted or conventional manual technique under local anesthesia. The robotic part of the procedure involved advancement of a cannula through the retina and stabilizing it during foot-controlled injection of up to 100 µL of TPA solution. We assessed surgical success, duration of surgery, adverse events, and tolerability of surgery under local anesthesia. RESULTS: The procedure was well tolerated by all participants and safely performed in all cases. Total duration of surgery, time taken to complete the injection, and retinal microtrauma were similar between the groups and not clinically significant. Subretinal hemorrhage was successfully displaced at 1 month postintervention, except for 1 control subject, and the median gain in visual acuity was similar in both arms. CONCLUSIONS: This first-in-human study demonstrates the feasibility and safety of high-precision robot-assisted subretinal drug delivery as part of the surgical management of submacular hemorrhage, simulating its potential future application in gene or cell therapy.
引用
- Cehajic-Kapetanovic J, Xue K, Edwards TL, et al. First-in-Human Robot-Assisted Subretinal Drug Delivery Under Local Anesthesia. Am J Ophthalmol. 2021. PMID: 34788592. doi:10.1016/j.ajo.2021.11.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。